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ABSTRACT
3,4-Methylenedioxymethamphetamine (MDMA) is a popular
recreational drug that has been shown to increase
serotonin and ·dopamine levels, yet little is know about
its long-term effects in brain. Recehtly, however, studies
examining the effects of prenatal MDMA exposure on brain
functioning have indicated that MDMA exposure may be
responsible for long-term cognitive deficits. Therefore,
in the present study we administrated MDMA (20 mg/kg twice
per day) to both male and female preweanling rats on
postnatal days

(PD) 11-20, to assess whether MDMA caused

permanent deficits in serotonergic and dopaminergic
functioning. We measured serotonin, 5-hydroxyindoleacetic
acid, dopamine, dihydroxyphenyleacetic acid levels, and
PKA activity in the striatum, prefrontal cortex, and
hippocampus on PD 90. MDMA pre-exposure caused significant
reductions in serotonin concentrations in both the
prefrontal cortex and hippocampus. In addition, the
striatum and prefrontal cortex showed significant
reductions in dopamine, however only in the prefrontal
cortex were significant declines in dihydroxyphenyleacetic
acid levels observed. MDMA pre-exposed rats showed a
significant decline in protein kinase A activity in both
prefrontal cortex and hippocampus. When considered
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together, this study provides the first evidence that
exposure to MDMA during the preweanling period has
long-term neurotoxic effects on both serotonergic and
dopaminergic systems.
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CHAPTER ONE
INTRODUCTION
3,4-Metheylenedioxymethamphetamine
(MDMA) Overview
3,4-Methylenedioxymethamphetamine (MDMA), popularly
known as "Ecstasy", continues to gain popularity as a
recreational drug (Cregg & Tracey, 1993; Cuomo, Dyment, &
Gammino, 1994; Ricaurte, Finnegan, Irwin,

&

Langston,

1990), despite compelling evidence that MDMA is a potent
toxic compound affecting both brain serotonergic (Green,
Cross, & Goodwin, 1995; Ricaurte, Byran, Stauss, Seiden, &
Schuster, 1985) and dopaminergic functioning (Hotchkiss &
Gibb, 1980; Ricaurte, Schuster, & Seiden, 1980; Seiden,
Fischman, & Schuster, 1975). Illicit use of MDMA did not
become popular until the lite 1980's among college
campuses and underground ·"rave" partieso The incidence of
MDMA usage has escalated rapidly, largeiy due to its
euphoria-inducing and mild stimulant properties. Although
first synthesized as a pharmacotherapeutic agent in the
early: 1900's (Shulgin, 1986), it was quickly abandoned
!

until the 1970's, when some mental health professionals
began using it in,an attempt to facilitate psychotherapy
(Greer, 1985; Greer & Tolbert, 1986; Shulgin & Nichols,
1978). Even though both the therapeutic communities and
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recreational drug users displayed intense interest in
MDMA, the Drug Enforcement Administration (DEA)
categorized MDMA as a Schedule I synthetic substance
(Lawn, 1986). Schedule I drugs have a high potential for
abuse and are not accepted for medical use in the United
States.
Due to the drastic increase in the abuse of MDMA,
researchers have begun to intensively investigate the
neurobiological effects of MDMA on various neuronal
parameters. Researchers using animals have shown that MDMA
affects motor, autonomic, and general central nervous
system (CNS)

functioning (Shulgin, 1986). These effects

are similar to those observed in humans and include
hyperactivity, excitability, aggressive behavior,
convulsions, muscular rigidity, mydriasis, and salivation
(Hardman, Haavik, & Seevers, 1973).
Evidence that MDMA causes brain damage is based on
experiments involving non-primates and primates. For
example, both acute and chronic treatment with MDMA
produces significant damage to serotonin (5-HT) neurons in
rat brain (Battaglia, Yeh,
DeLanney, Irwin,

&

&

De Souza, 1988; Ricaurte,

Langston, 1988). MDMA also alters

serotonergic functioning in primate brain, as this drug
causes regional decreases in 5-HT metabolites (e.g.,

2

5-hydroxyindoleacetic acid; 5-HIAA) and a reduction in
5-HT uptake sites (Insel, Battaglia, Johannessen, Marra, &
De Souza, 1989; Ricaurte et al., 1988). MDMA also disrupts
dopaminergic functioning by altering the activity of
dopamine (DA) transporters, and by reducing both tyrosine
hydroxylase (TH) activity and DA levels (Hotchkiss

&

Gibb,

1980; Metzer, Hanson, Gibb, & Fleckenstein, 1998; Nash &
Nichols, 1991; Wagner, Ricaurte,- Seideb, Schuster, Miller,
&

Westley, 1980). Decreased dopaminergic and serotonergic

neurotransmission has been implicated in cognitive
impairment and numerous psychiatric disorders (Kahn &
Davis, 1994; Maes & Meltzer, 1994); thus, it is important
to determine the neural mechanisms affected by MDMA
exposure.
Summary and Proposal
It appears that MDMA induces neurotoxicity in
serotonergic and dopaminergic neurons. The purpose of this
project is to assess the long-term effects of repeated
administration of MDMA on both serotonergic and
dopaminergic neuronal functioning. Specifically, male and
female rats will be given daily administrations of MDMA
(50 mg/kg twice per day) on postnatal days

(PD) 11-20.

Rats will be killed at PD 90 and samples from the dorsal
striatum, prefrontal cortex, and hippocampus will be
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assayed for 5-HT, 5-HIAA, DA, dihydroxyphenyleacetic acid
(DOPAC) levels, and protein kinase A (PK.A) activity.
Measuring these neurotransmitters (i.e., 5-HT and DA) is a
common method for assessing neurotoxicity. In addition,
PK.A will be measured because it is an important component
of second messenger systems associated with both 5-HT and
DA, and PK.A activity is reduced after repeated treatments
with amphetamine and methamphetamine (Crawford, Zavala,
Karper, Collins, Loring-Meier, Watson, & McDougall, 2000a;
Terwilliger, Beitner-Johnson, Sevarino, Crain, & Nestler,
1991). Thus, this study will attempt to determine whether
early exposure to MDMA causes neurotoxicity in 5-HT and DA
neurons or a decline in PK.A activity.
Serotonin Systems
Neuropharmacology
5-HT is a monoamine neurotransmitter found in both
the CNS and peripheral nervous system (PNS),. 5-HT plays a
variety of roles in neurological functioning. More
specifically, 5-HT has been implicated in the etiology or
treatment of various disorders, such as anxiety,
depression, schizophrenia, and obesity (Naughton,
Mulrooney, & Leonard, 2000). Serotonergic neurons are
principally located in several clusters· along the midline
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or the raphe of the brainstem. The dorsal raphe is
situated in the midbrain central gray matter on the
midline just below the sylvian aqueduct and the median
raphe is located ventrally on the midline (Feldman, Meyer,
&

Quenzer, 1997).
5-HT is synthesized in a two-step process from the

essential amino acid tryptophan. Tryptophan is the
rate-limiting step in the biosynthesis of 5-HT; therefore,
the amount of tryptophan in the brain determines the
amount of 5-HT produced. After tryptophan enters the
presynaptic terminal the enzyme tryptophan hydroxylase
converts tryptophan to 5-hydroxytryptophan (5-HTP). Amino
acid decarboxylase removes a carboxyl group from 5-HTP to
yield 5-HT (Cox & Nelson, 2000). Free-floating 5-HT is
rapidly metabolized by MAO and the resulting substance is
readily converted by aldehyde dehydrogenase to 5-HIAA.
Thus, 5-HIAA is the major metabolite of 5-HT. 5-HT is
removed from the synaptic cleft by either an active
reuptake process or by MAO. Like the dopaminergic reuptake
system, Na+/cl- is necessary for the 5-HT transporter to
function (Graham, Esnaud, Habert, & Langer, 1989;
Marcusson

&

Ross, 1990).

Molecular biology techniques have paved the way for
tremendous progress in 5-HT receptor identification. 5-HT
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can act presynaptically or postsynaptically, and can be
either excitatory or inhibitory. Thus, it.is no surprise
that more than 16 different 5-HT receptors have been
identified (Cryan & Leonard, 2000; Dubovsky & Thomas,
1995; Teitler

&

Herrick-Davis, 1994). Currently, 5-HT

receptors are classified according to their structure into
three major families of receptors: 5-HT1, 5-HT 2 , and 5-HT 3 •
These families of 5-HT receptors can be further subdivided
into a variety of receptor subtypes [e.g., 5-HT1A, 5-HTrn,
etc.]

(Bradley, Engel, Feniuk, Fozard, Humphrey,

Middlemiss, Mylechrane, Richardson, & Saxena, 1986; Zifa &
Fillion, 1992). With the exception of the 5-HT 3 receptor,
which is a ligand-gated ion channel, all other 5-HT
receptor subtypes are G-protein coupled receptors (Teitler
&

Herrick-Davis, 19~4)·. 5-HT1 receptors have a high

affinity for 5-HT and stimulation of these receptors
inhibits adenylase cyclase activity and opens a K+ channel
producing hyperpolarizations (Chen

&

Penington, 1996,

1997; Penington & Fox, 1995; Penington, Kelly, & Fox,
1993; Premkumar & Ahern, 1995). 5-HT 2 receptors are
low-affinity receptors and activation of these receptors
can either increase ca++ levels by stimulating
phosphoinositol hydrolysis or depolarize neurons by
closing K+ channels (Chen

&

Penington, 1997, 1996;
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Penington & Fox, 1995; Penington et al., 1993; Premkumar &
Ahern, 1995).
Neuroanatomy and Behavior
Serotonergic neurons originate in the brain stem and
project throughout the brain. More specifically, 5-HT
neurons can be divided into two distinct systems: the
caudal system and the rostral system (Sanders-Bush &
Canton, 1995; Tork, 1990). The caudal system, which is
consistent with Bl-B4 of Dahlstrom and Fuxe (1964),
originates in the median and paramedian medulla and caudal
pons, with axons terminating in the spinal cord (Tork,
1990). These descending pathways are involved in sensory,
motor, and autonomic functioning (Whitaker-Azmitia, 1991)
The rostral system, which is consistent with the B5-B9
cell groups (Dahlstrom

&

Fuxe, 1964), originates in raphe

nuclei of the rostral pons, mesencephalon, caudal linear
nucleus, nucleus pontis oralis, and the supralemniscal
region (Nieuwenhuys, 1985; Tork, 1990). Fibers projecting
from these neurons ascend to the diencephalon, basal
ganglia, limbic system, and cortex via two distinct fiber
tracts: the ventral and dorsal ascending pathways
(Nieuwenhuys, 1985).
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Dopamine Systems
Neuropharmacology
DA was initially considered to be merely an
intermediate step in the synthesis of -norepinephrine and
epinephrine. In the late 1950's, however, DA was
discovered to be a neurotransmitter involved in the
control of motor movement and emotional behaviors (Seeman,
1995). DA is a catecholamine neurotransmitter synthesized
in nerve terminals in the hypothalamus, arcuate nucleus,
caudate, nucleus acccumbens, prefrontal cortex,
hippocampus, and various other areas of the CNS (Feldman
et al., 1997; Wolf & Roth, 1987). DA is impermeable to the
blood brain barrier, thus it must be synthesized in the
CNS (Cooper, Bloom,

&

Roth, 1996). Specifically, tyrosine

readily passes the blood-brain barrier where it is
actively absorbed into the brain. Upon entry into DA
terminals, tyrosine is converted to
L-dihydroxyphenylalanine (L-DOPA) by the enzyme TH. The
rate at which this conversion takes place is limited by
the amount of TH present, thus TH is the rate-limiting
step in DA synthesis. L-DOPA is then quickly converted to
DA by the enzyme DOPA decarboxylase (Roth
1995) .

8

&

Elsworth,

After being released into the synaptic cleft, the DA
transporter, a Na+/cl- dependent mechanism, transports DA
in either direction depending on the concentration
gradient (Krueger, 1990). Thus, in the normal case DA is
transported from the synaptic cleft to the presynaptic
terminals where it is either repackaged into vesicles or
metabolized into DOPAC by the enzyme monoamine oxidase
(MAO). Extracellular DA can be metabolized by the enzyme
catechol-0-methyltransferase (COMT) and converted into
homovanillic acid (HVC), one of the primary metabolites of
DA (Kopin, 1985).
DA can inhibit or excite other neurons, depending on
the properties of the receptor stimulated. There are two
families of DA receptors differentiated on the basis of
their pharmacology: Di-like and D2 -like receptors
(Civelli, 1995; Kebabian

&

Calne, 1979). These two

families of receptors include five structurally distinct
subtypes: Di, D2 , D3 , D4 , and D5 receptors (Cooper et al.,
1996). The Di and D5 receptors

(i.e., Di-like receptors)

are closely related, as they stimulate adenylyl cyclase
activity, increase cyclic AMP (cAMP), and are excitatory.
In contrast, D2 , D3 , and D4 receptors (i.e., D2 -like
receptors)

inhibit adenylyl cyclase activity, decrease
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cAMP activity, and are inhibitory (Andersen, Gingrich,
Bates, Dearry, Falardeau,

&

Senogles, 1990).

Neuroanatomy and Behavior
Dopaminergic neurons are found in small and large
circuit pathways in the CNS. The nigrostriatal pathway,
one of the larger pathways, is the primary DA pathway
projecting from the substantia nigra and terminating in
the caudate and putamen (Bannon

&

Roth, 1983).

Degeneration of dopaminergic neurons in the .nigrostriatal
pathway is responsible for motor deficits associated with
Parkinson's disease (Bannon

&

Roth, 1983; Cooper et al.,

1991). DA neurons also compose the mesolimbic and
mesocortical pathways, which originate in the ventral
tegmental area (VTA) and project to parts of the limbic
system and cortex, respectively. DA neurons in the limbic
system modulate both locomotor activity and motivation
(LeMoal

&

Simon, 1991); whereas, DA neurons projecting to

the cortex appear to be involved in cognition and
emotional behavior (Wolf, Deutch, & Roth, 1987). Excess
dopaminergic transmission within the mesolimbic and
mesocortical systems has been linked to schizophrenia
(Kahn

&

Davis, 1994), as well as some of the motor and

attention problems associated with Tourette's disorder and
attention deficit hyperactivity disorder [ADHD]
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(Comings,

Comings, Muhleman, Dietz, Shahbahrami, Tast, Knell,
Koscsis, Baumgarten, Kovacs, Levy, Smith, Borison, Evans,
Klein, MacMurray, Tosk, Sverd, Gysin, & Flanagan, 1991;
George, Robertson, Costa, Ell, Trimble, Pilowsky,

&

Verhoeff, 1994).
Behavioral Impact of MDMA Exposure
A substantial number of studies using various species
have examined the behavioral effects induced by MDMA.
While many studies have assessed behavioral changes
induced by acute MDMA treatment other studies. have
examined the cognitive impact of repeated MDMA exposure.
Acute Behavioral Effects of MDMA
The acute behavioral effects characteristic of MDMA
treatment are caused by a rapid decline in TPH and reduced
5-HT activity, coupled with increased DA release.
Behavioral effects of acute MDMA treatment have been
assessed through a variety of paradigms, including the
elevated plus-maze, open field, skilled paw-reach tasks,
and threat and attack paradigms. Paradigms designed to
assess anxiety sµggest that MDMA's effects are complex.
For example, on the elevated plus-maze, lower doses of
MDMA (4 mg/kg) produce an anxiogenic effect in mice,
whereas at higher doses (20 mg/kg) anxiolytic effects are

11

apparent (Lin, Burden, Christie, & Johnson, 1999). In
contrast, rats given medium to high doses of MDMA display
an anxiogenic response when assessed on·an elevated
plus-maze (Bhattacharya, Bhattacharya,

&

Ghosal, 1998)

When assessed in the open field, rodents treated with MDMA
exhibit a decrease in anxiety-related behaviors and an
increase in locomotor activity (Meehan, Moran, & Elliot,
2002). Significant impairments in spontaneous locomotor
activity and skilled motor function are also observed
after MDMA exposure (Marston, Reid, Lawrence, Oliverman, &
Butcher, 1999). Lastly, MDMA reduces aggressive behaviors
in rodents when assessed on threat and attack paradigms
(Miczek

&

Haney, 1994). The latter findings are

interesting, because reductions in 5-HT activity typically
increase aggressive behaviors in rodents.
In addition to examining the unlearned effects of
MDMA exposure, a number of laboratories have examined
whether MDMA causes cognitive impairments (Bolla, Mccann,

& Ricaurte, 1998; Curran & Travill, 1997; Morgan, 1999).
Various tests of memory function (e.g., delayed non-match
to place and self-ordered spatial search tasks) have
demonstrated that acute MDMA treatment induces cognitive
deficits (Marston et al., 1999; Taffe, Weed, Davis,
Huitron-Resendiz, Schroeder, Parsons, Henriksen, & Gold,
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2001). More specifically, on the delayed non-match to
place task, rats treated with MDMA display severe memory
impairments (Marston et al., 1999). In addition, acute
MDMA treatment causes a dose-dependent decrease in both
accuracy and response rates on a delayed non-match to
sample task in pigeons (Lesage, Clark, & Poling, 1993)
Rhesus monkeys perform poorly on cognitive battery
measures after acute treatment with MDMA (Taffe et al.,
2001). These alterations in both unlearned behaviors and
cognitive functioning are credited to neurochemical
changes caused by acute MDMA treatment.
Long-Term Behavioral Effects of MDMA
It has been well documented that administration of
MDMA, either in a single high dose or multiple doses,
produces long-term damage to 5-HT nerve terminals, but the
long-term behavioral impact of MDMA neurotoxicity remains
unclear (Molliver, Berger, Mamounas, Molliver, O'Hearn, &
Wilson, 1990; O'Hearn, Battaglia, De Souza, Kuhar, &
Molliver, 1988; O'Shea, Granados, Esteban, Colado, &
Green, 1998). The neurotoxic effects of MDMA exposure
first appear between 1 and 7 days after drug
administration and are characterized by a decrease in 5-HT
concentrations, loss in functional 5-HT uptake sites, and
degeneration of serotonergic terminals (McKenna &
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Peroutka, 1990; Schmitt, 1987; Schmitt & Kehen, 1990).
Brain levels of DA and its metabolites are not affected by
low doses of MDMA, but are depleted after higher doses.
This pattern of results suggests that MDMA is capable of
inducing DA neurotoxicity, and that MDMA is more toxic to
5-HT than DA neurons (Commins, Vosmer, Virus, Woolverton,
Schuster, & Seiden, 1987; Laverty & Logan, 1990; Miller &
O'Callaghan, 1995).
There is some evidence, although it is not
conclusive, that MDMA exposure has long-term impact on
behavioral and cognitive performance. On the elevated
plus-maze and open field tasks, MDMA-treated rodents
exhibit. reduced anxiety and increased risk-taking behavior
(Meehan et al., 2002). However, when behavior is assessed
using a social interaction paradigm, rats given MDMA have
fewer social interactions than their controls (Fone,
Beckett, Topham, Swettenham, Ball,

&

Maddocks, 2002),

suggesting that MDMA causes increased social anxiety
(File, 1980). Studies using rodents indicate that MDMA
exposure causes long-term cognitive deficits. For example,
rats treated with MDMA display deficits on a delayed
non-matching to position working memory task for up to 19
days after drug treatment (Marston et al., 1999). This
cognitive deficit, which suggests that MDMA impairs

14

short-term memory, is consistent with the finding that
MDMA causes degeneration of serotonergic neurons in the
cortex and hippocampus (Marston et al., 1999). In
contrast, the performance of rats on a .delayed alternation
task was generally unaffected by neurotoxic doses of MDMA
(Ricaurte, Markowska, Wenk, Hatzidimitriou, Wlos, & Olton,
1993). Consistent with the latter study, primates display
an absence of learning impairments after exposure to MDMA
(Frederick, Ali, Sl{kker, Gilliam, Allen, & Paule, 1995).
Therefore, while it has been well documented that
MDMA-induces neurotoxicity, much remains to be discovered
about the behavioral consequences that accompany long-term
depletion of 5-HT and DA.
It is uncertain whether MDMA exposure causes
neurotoxicity in humans, but emerging evidence indicates
that repeated MDMA exposure results in performance
decrements in neurocognitive functioning (Morgan, 1999;
Rodgers, 2000). The manifestations of these deficits, in
terms of altered cerebral functioning and behavioral
changes, range from neuroendocrine impairments to deficits
in verbal memory and reasoning, short-term memory,
semantic recognition, and visual memory (Broening,
Morford, Imman-Wood, Fukumura, & Vorhees, 2001; Marston et
al., 1999; Morgan, 1999; Rodgers, 2000). Therefore,
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despite some conflicting reports, there is ample evidence
that MDMA exposure has long-term behavioral impact on both
animals and humans. Understanding the nature of this
MDMA-induced neurotoxicity may be important for the
treatment of personality disorders, impulsive/aggressive
behavior, and learning impairments.
MDMA-Induced Neurotoxicity:
Serotonin Systems
MDMA exposure causes characteristic patterns of
neurotoxicity, as MDMA exerts marked effects on
serotonergic systems in brain (Battaglia, Yeh, O'Hearn,
Molliver, Kuhar, De Souza, 1987; Schmidt, 1987; Sprague,
Everman, & Nichols, 1998; White, Obradovic, Imel, &
Wheaton, 1996). For example, neurochemical studies in
rodents and primates have demonstrated that MDMA exposure
results in a profound decrease in 5-HT concentrations
(Battaglia et al., 1987; Commins et al., 1987; Stone,
Stahl, Hanson, & Gibb, 1986). In addition, MDMA exposure
reduces 5-HT transporters and synaptosomal uptake activity
(Stone et al., 1986), d~creases the density of 5-HT axon
terminals (Battaglia et al., 1987; Huether, Zhou,

&

Ruther, 1997; O'Hearn et al., 1988), and causes declines
in 5-HIAA and TPH levels (Battaglia et al., 1987; Schmidt,
1987; Stone et al., 1986). As mentioned previously, TPH is
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the rate-limiting step in 5-HT synthesis, and reductions
in brain TPH activity may be one of the initial neurotoxic
effects produced by MDMA (Schmidt

&

Kehne, 1990).

The neurotoxic effects of' MDMA exposure are often
quantified by assessing reductions in transporter site
density using [ 3 H]-paroxetine (Battaglia et al., 1987). In
addition, neurotoxic damage to 5-HT nerve terminals can be
determined by measuring decreases in 5-HT and 5-HIAA
levels (Battaglia et al., 1987; Hewitt

&

Green, 1994;

Stone et al., 1986). Advanced brain imaging techniques,
such as positron emission tomography (PET), can also be
used to assess neuronal damage. For example, PET imaging
indicates that MDMA exposure causes significant reductions
in the number of 5-HT transporters in various brain
regions (Commins et al., 1987; Mccann, Szabo, Scheffel,
Dannals,

&

Ricaurte, 1998). Most typically, damage to 5-HT

neurons has been demonstrated in the hippocampus,
neocortex, striatum, thalamus, and amygdala (Molliver et
al., 1990; O'Hearn et al., 1988).
Acute MDMA Exposure
Acute treatment with MDMA can induce neurotoxicity,
but the extent of the damage varies according to dose.
Evidence of neuronal damage has been revealed by the
application of silver staining techniques, which have
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shown that a single exposure to MDMA (40 mg/kg) produces a
substantial increase (90%) in the number of degenerating
axons and nerve terminals (Commins et al., 19_87; Slikker
et al., 1988). Similarly, a single injection of 20 or 40
mg/kg MDMA is capable of inducing 5-HT toxicity in the
striatum, hippocampus, and cortex; however, neurotoxicity
in the hypothalamus was only induced by _an injection of 40
mg/kg MDMA (Commins et al., 1986). Acute treatment with a
lower dose (10 mg/kg) of MDMA caused a significant decline
in the density of 5-HT uptake sites in prefrontal cortex
of rat brain (Battaglia et al., 1988). Likewise, a single
injection of 10, 15, or 20 mg/kg MDMA caused a significant
decline in TPH activity and an increase in
transporter-mediated 5-HT in the neostriatum, hippocampus,
and hypothalamus of adult rats (Battaglia et al., 1988;
Ricaurte et al., 1988; Schmidt & Kehne, 1990; Stone,
Merchant, Hanson, & Gibb, 1987), while an acute injection
of 15 mg/kg MDMA reduced 5-HT and 5-HIAA levels by more
than 50% in the cortex, hippocampus, nucleus accumbens and
striatum (Mayerhofer, Kovar, & Schmidt, 2001; O'Shea et
al., 1998). 5-HT neurons in the cerebral cortex of monkey
brain also show structural changes and axonal damage after
exposure to 5 mg/kg MDMA (Ricaurte et al., 1988).
Therefore, it is clear that an acute injection of a
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moderate to high dose (i.e., 10-40 mg/kg) of MDMA causes
substantial 5-HT neurotoxicity; whether lower doses of
MDMA induce neurotoxicity is more uncertain.
Chronic MDMA Exposure
Repeated administration of MDMA causes 5-HT
neurotoxicity in animals. MDMA-induced neurodegeneration
appears to be dosage- and frequency-dependent. Rats
treated with multiple low doses of MDMA (4 mg/kg), either
once daily over a four day period or twice weekly over an
eight week period, show no evidence of 5-HT neurotoxicity
(O'Shea et al., 1998). When the same study was replicated
with slight alterations in the frequency of MDMA exposure
(4 mg/kg twice daily for a four day period) significant
reductions in 5-HT uptake sites were reported (O'Shea et
al., 1998). In rhesus monkeys, multiple injections with a
low dose of MDMA (2.5 mg/kg twice daily for four days)
reduced 5-HT levels in the hippocampus (Ali, Newport,
Scallet, Binienba, Ferguson, Bailey, Paule, &.Slikker,
1993). This is of particular interest because squirrel
monkeys exposed to 2.5 mg/kg MDMA twice a month for four
months showed no long-term changes in 5-HT or 5-HIAA
levels or 5-HT transporter sites (Ricaurte et al., 1988)
More frequent treatment with MDMA (5 mg/kg twice daily for
four days) produces substantially more neurotoxicity in

19

monkey brain, as immunostaining indicated that
serotonergic axons were swollen and fragmented (Ricaurte
et al., 1988). Based on these studies, it appears that the
effects of MDMA are both dosage and frequency dependent,
with larger doses and more frequent drug administrations
producing greater neurotoxicity (Ali et al., 1993;
Battaglia et al., 1988; O'Shea et al., 1998; Ricaurte et
al., 1988).
Similarly, studies have reported a decrease in
serotonergic functioning with multipie ·injections of
higher doses of MDMA. Repeated treatment with 10-40 mg/kg
MDMA reduces THP activity, 5-HT levels,. and 5-HIAA levels
by at least 50-60% in the neostriatum, hippocampus, and
cortex of rat brain (Battaglia et al., 1987; Commins,
1986; Gibb et al.~ 1990). Likewise, rats given eight
consecutive injections of 20 mg/kg MDMA over a four day
period demonstrated up to a 76% depletion of 5-HT
transporters in the prefrontal cortex, hippocampus,
striatum, hypothalamus, and midbrain (Battaglia et al.,
1987; Obradovic, Imel, & White, 1996; Schmidt, 1994).
Thus,. there is an abundance of data showing that repeated
treatment with moderate to high doses of MDMA causes
marked 5-HT neurotoxicity and depressed 5-HT functioning
(Gibb et al., 1990).
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MDMA-Induced Neurotoxicity:
Dopamine Systems
Several in vivo and in vitro studies have shown that
MDMA robustly evokes the release of DA and induces DA
neurotoxicity (Nash & Nichols, 1991; Nash & Yamamoto,
1992; Shankaran & Gudelsky, 1998; Yamamoto & Spanos,
1988). Furthermore, it has been suggested that there is an

intimate relationship between DA release and the long-term
depletion of 5-HT (Nash

&

Nichols, 1991). That is, MDMA

releases DA through two separate mechanisms: first, by
directly releasing DA via the transporter (Johnson,
Hoffman, Nichols, 1986; Schmidt, Levin, & Lovenburg, 1987)
and, second, by indirectly releasing DA through actions on
5-HT systems [the release of 5-HT activates 5-HT receptors
which stimulates DA synthesis and release]

(~cCann &

Ricaurte, 1993; Nash, 1990). Evidence for the first
mechanism of action is provided by studies showing that
selective DA inhibitors (i.e., GBR 12909 and
a-methyl-p-tyrosine) suppress MDMA-induced DA and 5-HT
release (Brodkin, Malyala,

&

Nash, 1993; Stone, Johnson,

Hanson, & Gibb, 1988). Alt0ough MDMA causes only modest
depletions of DA, relative to 5-HT, MDMA does induce
significant DA neurotoxicity in the hippocampus, nucleus
accumbens, striatum, and other regions of the brain
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(Johnson et al., 1986; Yamamot.o, Nash, & Gudelsky, 1995;
Yamamoto & Spanos, 1988)
Acute MDMA Exposure
Researchers have found that MDMA-induced
neurotoxicity not only requires· 5-HT release, but also DA
efflux from cells (Rudnick & Wall, 1993). Acute treatment
with low to moderate doses of MDMA (1-20 mg/kg) causes a
dose-dependent elevation of extracellular DA levels in the
nucleus accumbens and hippocampus (Kankaanpaa, Meririnne,
Lillsunde, & Seppala, 1998; Shankaran & Gudelsky, 1998).
This is of particular interest, because extracellular DA
promotes free radical formation and inhibits•
glutamate-evoked firing: two mechanisms responsible for
neurotoxicity (Cadet, Ladenheim, Hirata, Rothman, Ali,
Carson, Epstein,

&

Misra, Murray,

Green, 1997i Obradovic et al., 1996;

&

Morgan; 1995; Colado, O'Shea, Grandos,

Shankaran, Yamamoto, & Gudelsky, 1999; White, Duffy, &
Kalivas, 1994; Yamamoto

&

Spanos, 1988). In addition, rats

exposed to MDMA (1.0, 3.0, or 9.0 mg/kg) show
significantly depressed DOPAC concentrations, however HVA
concentrations were only reduced after an acute injection
of 9:0 mg/kg MDMA (Kankaanpaa et al., 1998). Curiously, an
earlier study reported that moderate to high doses (10,
20, or 40 mg/kg) of MDMA does not cause DA neurotoxicity
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in any of the brain regions examined (Commins et al.,
1986). These results are consistent with other reports
indicating that MDMA, given at doses which induce 5-HT
neurotoxicity, leaves the DA system virtually unaltered
(Battaglia et al., 1987; Colado, O'Shea, Granados,
Esteban, Martin, & Green, 1999; Schmidt & Kehne, 1990)
Due to these conflicting results, it remains uncertain
whether acute MDMA exposure produces measurable DA
neurotoxicity.
Chronic MDMA Exposure
In contrast to the acute administration literature,
there is more consistent evidence that repeated treatment
with high doses of MDMA causes DA neurotoxicity (Green et
al., 1995; Logan, Laverty, Sanderson, & Yee, 1988).
Although dopaminergic toxicity has been evidenced in both
primates and non-primates, many of the DA toxicity studies
use a mouse model (Johnson, O'Callaghan, & Miller, 2002;
Johnson, Shvedova, Kisin, O'Callaghan, Kommineni, &
Miller, 2002; O'Shea, Esteban, Camarero, Green, & Colado,
2001). More specifically, mice treated with MDMA show long
lasting depletions of striatal DA, HVA, DOPAC, and TH
(O'Callaghan & Miller, 1994).
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Factors Affecting Neurotoxicity
Protection from Serotonergic and Dopaminergic
Neurotoxicity
In vivo and in vitro studies have utilized selective
inhibitors of monoamine transporters to analyze the
effects of MDMA on serotonergic and dopaminergic neuronal
systems. Brain dialysis studies have shown that
pretreating rats with dopaminergic receptor antagonists
(e.g., haloperidol), DA depletive agents
(~-methyl-p-tyrosine), selective DA transport inhibitors
(e.g., GBR 12909), or selective 5-HT transport inhibitors
(e.g., fluoxetine) will prevent MDMA-induced neurotoxicity
to DA and 5-HT neurons (Bradberry, 1994; Brodkin et al.,
1993; Colado et al., 1999; Green et al., 1995; Schmidt et
al., 1991; Stone et al., 1988). For example, rats
pretreated with haloperidol show an attenuated loss of
5-HT transporter sites, suggesting that DA release
contributes to 5-HT transporter destruction (Hewitt &
Green, 1994). Furthermore, GBR-12909 not only inhibits
MDMA-induced DA release but attenuates 5-HT neurotoxicity
(Koch & Galloway, 1997). MDMA-induced 5-HT neurotoxicity
can also be reduced by serotonergic antagonists
[fluoxetine, WAY 100135, and methiothepin]

(Obradovic et

al., 1996). For example, pretreatment with selective 5-HT
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reuptake inhibitors [SSRI's]

(e.g., fluoxetine or

citalopram) block both MDMA-induced 5-RT release and
subsequent toxicity (Bradberry, 1994; Gudelsky & Nash,
1996; Schmidt, 1987). Thus, when the release of DA and
5-RT are blocked by antagonist drugs, the ability of MDMA
to induce neurotoxicity is. significantly attenuated.
Effects of Ambient Temperature
Researchers have also investigated the influence of
ambient temperature on MDMA-induced neurotoxicity, as it
has been repeatedly shown that ambient temperature is a
critical factor in determining the extent of MDMA-induced
neurotoxicity (Broening, Bowyer, & Slikker, 1995; Malberg

& Seiden, 1998; Russel & Laverty, 2001). For example,
MDMA-treated rats maintained at a lower ambient
temperature (20° or 22° C) display no 5-RT neurotoxicity,
whereas MDMA-treated rats maintained at a higher ambient
temperature (26°, 28°, or 30° C) show significant
decreases in 5-RT and 5-RIAA levels (Malberg & Seiden,
1998). Ambient temperature probably plays a vital role in
determining the extent of toxicity because hyperthermia is
a mechanism responsible for neuronal death (Bowyer, Gough,
Slikker, Lipe, Newport, & Rolson, 1993; Bowyer, Tank,
Newport, Slikker, Ali, & Rolson, 1992). Thus, hyperthermia
is critical for MDMA-induced neurotoxicity, and this
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neurotoxicity can be attenuated by either lowering core
ambient temperature or by coadministering drugs that
produce a hypothermic response (Hewitt & Green, 1994;
Malberg et al., 1996).
MDMA-Induced Effects on Behavior
and Neural Development
Prenatal Drug Exposure
Several teratological studies have attempted to
identify possible adverse effects caused by prenatal drug
exposure. This is of importance because clinical studies
have reported that human infants exposed prenatally to
psychostimulant drugs exhibit many neurobehavoral
problems, such as increased irritability, impairments in
orientation and motor ability reflexitivity, and
depression of interactive behavior (Chasnoff,· Burnes,
Schnoll,

&

Burnes, 1985; Chasnoff, Griffith, MacGregor,

Derkes, & Burnes, 1989; Chasnoff & Lewis, 1987). Animal
models have shown long-term alterations in behavior after

in utero drug exposure. These alterations include
modifications in locomotor activity and deficits in
information acquisition (Heyser, Chen, Miller, Spear, &
Spear, 1990). For instance, one study reported that
prenatal cocaine exposure results in long-lasting
alterations in brain metabolism, including decreased
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glucose utilization along with increased D1 receptor
concentrations in the substantia nigra of adult male
offspring (Dow-Edwards, Freed, & Fico, 1990).
Surprisingly, relatively few studies have examined
the effects of prenatal MDMA exposure on brain functioning
(Aguirre, Barrionuevo, Lasheras,

&

Del Rio, 1998; Colado

et al., 1997; St. Omer, Ali, Rolson, Duhart, Scalzo, &
Slikke_r, 1991). Although MDMA induces neurotoxicity in
adult rats, results indicate that administering MDMA
during gestation has no effect on postnatal neurochemical
development of the 5-HT system (St. Omer et al., 1991)
More specifically, pregnant rats administered varying
doses of MDMA (2.5 and 10.0 mg/kg on alternate gestational
days 6-18) had offspring with normal numbers of 5-HT
transporters, and 5-HT and 5-HIAA levels remained
unaffected (St. Omer et al., 1991). This is of interest
because MDMA caused significant reductions in the 5-HT and
5-HIAA levels of the dams (St. Omer et al., 1991).
When all of these results are considered together, it
is surprising that MDMA exposure does not affect neonates.
One possibility is that MDMA lacks impact because neonates
have underdeveloped transporter mechanisms (St. Omer et
al., 1991). Alternatively, extracellular DA levels may not
be great enough to produce oxidative stress in 5-HT
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terminals (Aguirre et al., 1998) or neonates may have a
higher capacity to scavenge free radicals (Colado et al.,
1997; Sprague et al., 1998). In any event, it appears that

in utero MDMA exposure does ··not induce measurable
neurotoxcicty in rats.
Postnatal Drug Exposure
Studies examining the neurochemical consequences of
MDMA exposure during the early pos~natal period are
sparse. However, most studies suggest that preweanling
rats, like neonates, are resistant to MDMA-induced
neurodegeneration (Aguirre et al., 1998; Broening et al.,
1994). In contrast, a recent report indicates that early
postnatal MDMA exposure does indeed have long-term
cognitive effects (Broening et al., 2001). The study
focused on two dosing periods (postnatal day [PD] 1-10 and
PD 11-20) and four doses of MDMA (0, 5.0, 10.0, and 20.0
mg/kg, given twice daily). Results indicated that MDMA
exposure on PD 11-20 significantly disrupted both
sequential and spatial learning of rats tested on a
Multiple-T water maze (Broening et al., 2001). More
specifically, PD 11-20 rats exhibited consistent deficits
in se'quential learning, measured in terms of errors and
escape latencies on the Multiple-T water maze, whereas
rats given MDMA on PD 1-10 did not show any behavioral
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deficits (Broening et al., 2001; Vorhees, Ahrens,
Acuff-Smith, Schilling,

&

Fisher, 1994). Therefore, it.is

apparent that repeated treatment with MDMA during the
preweanling period has long-term behavioral impact. The
neural mechanisms responsible for these behavioral effects
are uncertain, but probably reflect long-term changes in
the functioning of 5-HT or DA systems, because MDMA acts
as an agonist at 5-HT and DA synapses.
Hypotheses
In adult animals, repeated exposure to MDMA causes
5-HT neurotoxicity. In particular, MDMA induces a massive
release of 5-HT, resulting in depleted levels of 5-HT,
reduced concentrations of 5-HIAA, decreased activity of
TPH, and neurodegeneration of 5-HT axon terminals. In
addition to altering 5-HT systems, MDMA, to a lesser
extent, impacts DA systems. The purpose of this thesis,
therefore, was to determine whether exposing rats to MDMA
during the preweanling period causes long-term measurable
changes on various indices of 5-HT and_DA functioning. The
preweanling rat was chosen as the animal model because
Broening et al.

(2001_) have -recently shown that early

postnatal MDMA exposure causes long-term learning and
memory deficits. It was hypothesized that rats exposed to
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repeated high doses of MDMA would show a decreased levels
of 5-HT, 5-HIAA, DA, DOPAC and reduced PKA activity in
dorsal striatum, prefrontal cortex, and hippocampus. These
neuronal changes would be consistent with the hypothesis
that repeated MDMA exposure during the preweanling period
causes long-term damage to 5-HT and DA neurons in rat
brain.
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CHAPTER TWO
METHODS AND MATERIALS
Animals and Rearing Conditions
Nulliparous female (151-175 g) Sprague-Dawley CD rats
were obtained from Charles River Laboratories (Raleigh,
NC). Rats were allowed to acclimate to housing conditions
in the vivarium at the Cincinnati Children's Hospital
Research Foundation for at least two weeks prior to
breeding. Rats were pair housed in polycarbonate cages
with lights on from 6:00 to 20:00. Food and water were
freely available. On the day of breeding, one female was
placed with one male Sprague-Dawley CD rat in a hanging
wire cage until a sperm plug was detected [embryonic day O
(ED O)], or until the female had_been with the. male for 2
weeks. Two weeks after being placed with the male, the
females were transferred back to polycarbonate cages and
singly housed. The presence of a litter was checked twice
daily starting on ED 21 and the day of birth was
considered postnatal day O (PD 0). Litters remained
undisturbed until PD 1, at which time litters were culled
to ten pups (six males and four females). Subjects were
treated according to the National Institute of Health
guidelines for the care and use of laboratory animals
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(Principles of Laboratory Animal Care, NIH Publication

#85-23) under research protocols approved by the
Institutional Animal Care and Use Committees of the
Cincinnati Children's Hospital Research Foundation and
California State University, San Bernardino.
In Vivo MDMA Administration
Each animal in the litter was randomly assigned to
receive either MDMA or saline (n = 7 males and females per
group). MDMA HCl

(20 mg/kg, expressed as the freebase) or

saline vehicle were administered twice daily from PD 1120. MDMA and saline were injected subcutaneously in the
back at a volume of 3 ml/kg. Injection sites were rotated
to ensure the surrounding dermis did not become
aggravated. Animals were weighed prior to each injection
and thereafter at weekly intervals. On approximately PD 60
the animals were shipped to the vivarium at California
State University, San Bernardino. Rats were left
undisturbed until PD 90, when they were killed by rapid
decapitation. Brains were quickly removed and dorsal
striatal (i.e., caudate~putamen), prefrontal cortex, and
hippocampus were dissected on dry ice and stored at -80°C
until time of assay.
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Protein Kinase A (PKA) Assay
PKA assays were performed using the Protein Kinase A
(cAMP-dependent protein kinase) Assay System protocol
(Life Technologies, Grand Island, NY) with slight
modifications. Briefly, frozen striatal and prefrontal
cortex sections were placed in homogenization buffer [50
mM Tris

(pH 7.4), 100 ng/ml leupeptin, 100 ng/ml

aprotinin, and 5 mM EDTA] and homogenized using a
hand-held Teflon homogenizer. Protein concentrations were
determined using the Bio-Rad Protein Assay (Bio-Rad
Laboratories, Hercules, CA) based on the method of
Bradford (1976), using bovine serum albumin (BSA) as a
standard.
Duplicate striatal homogenates containing 4 µg of
protein for each subject were incubated for 5 min at 30°C
in phosphorylation buffer [50 mM Tris (pH 7.4), 10 mM
MgC1 2 , and 0.25 mg/ml BSA], containing 50 µg of kemptide
and 100 µM [y- 32 P]ATP (ICN, Costa Mesa, CA). In addition,
the buffer contained either cAMP (10 µM)

or PKI(6-22)

amide (1 µM/reaction). Following incubation, the
phosphorylation mixture was blotted on phosphocellulose
units (SpinZyme Format). Phosphocellulose units were
centrifuged at 20,000 x g £or 30 s, upon completion 500 ml
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wash solution and 75 mM phosphoric acid were added and the
samples were centrifuged again. Buckets were then
transferred into a new receptacle and 500 ml of wash
solution was added and centrifuged at 20,000 x g for 30 s.
Filters were then placed in scintillation fluid and
quantified by liquid scintillation spectrometry.
cAMP-dependent PKA activity was defined as the difference
between PKA activity in the presence of cAMP and that
measured in the presence of PKI.
Serotonin (5-HT) and 5-Hydroxyindoleacetic Acid
(5-HIAA) Content Assays
Frozen striatal, prefrontal cortex, and hippocampal
sections were sonicated in 10 volumes of 0.1 N HC1O 4 and
centrifuged at 20,000 x g for 30 min at 4°C. The
supernatant was then filtered through a 0.22 µm
centrifugation unit at 2,000 x g for 5 min at 4°C. The
remaining pellet from each tissue sample was resuspended
in 0.1 N HC1O 4 and used for protein determination. Twenty
microliters of the resulting extracts were then assayed
for 5-HT and 5-HIAA using high performance liquid
chromatography (582 pump and an MD-150 column; ESA,
Chelmsford, MA) with electrochemical detection (Coulochem
II; ESA). The mobile phase consisted of 75 mM NaH 2 PO4 ,
mM 1-octane sulfonic acid, 1o·mM EDTA, and 10%
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1.4

acetonitrile

[MD-TM Mobile Phase (pH 3.1); ESA] and was

pumped at a rate of 0.5 ml/min.
Dopamine (DA) and Dihydroxyphenyleacetic Acid
(DOPAC) Content Assays
Frozen striatal, prefrontal cortex, and hippocampal
sections were sonicated in 10 volumes of 0.1 N HC1O 4 and
centrifuged at 20,000 x g for 30 min at 4°C. The
supernatant was then filtered through a 0.22 µm
centrifugation unit at 2,000 x g for 5 min at 4°C. The
remaining pellet from each tissue sample was resuspended
in 0.1 N HC1O 4 and used for protein determination. Twenty
microliters of the resulting extracts were then assayed
for DA and DOPAC using high performance liquid
chromatography (582 pump and an MD-150 column; ESA,
Chelmsford, MA) with electrochemical detection (Coulochem
II; ESA). The mobile phase consisted of 75 mM NaH 2 PO 4 , 1.4
mM 1-octane sulfonic acid, 10 mM EDTA, and 10%
acetonitrile

[MD-TM Mobile Phase (pH 3.1); ESA] and was

pumped at a rate of 0.5 ml/min.
Data Analysis
Analyses of variance (ANOVA) were used to analyze
PKA, DA, DOPAC, 5-HT, and 5-HIAA data. Litter effects were
controlled by treating litter as a random factor in all
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analyses (see Hughes, 1979). In all cases, alpha were set
at 0.05.
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CHAPTER THREE
· RESULTS
Effects of MDMA on Serotonergic
Funct,ioning
Rats pre-exposed to MDMA during the preweanling
period had significantly lower 5-HT levels in the
prefrontal cortex than saline controls (see upper graph,
Figure 1)

[drug main effect, F(l,18) = 12.22, p < .01].

5-HIAA levels in the prefrontal cortex also appeared to be
depressed relative to saline controls, but the differences
between the saline- and MDMA-pre-exposure groups did not
reach statistical significance (see lower graph, Figure
1) .

Overall, when compared to saline controls, MDMA
significantly lowered 5-HT levels in the hippocampus (see
upper graph, Figure 2)

[drug main effect, F(l,18) = 87.06,

p < .01]. In addition, male rats had lower levels of
5-HIAA then females

p

<

[sex main effect, F(l,18) = 7.53,

.05]. MDMA pre-exposure did not affect 5-HT or 5-HIAA

levels in the striatum (see Figure 3).
Effects of MDMA on Dopaminergic
Functioning
Examination of the prefrontal cortex revealed
significantly lower DA levels in rats pre-exposed to MDMA
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during the preweanling period (see upper graph, Figure 4)
[drug main effect, F(l,18) = 5.83, p

<

.05]. Unexpectedly,

DOPAC levels varied according to sex, since male rats
displayed significantly lower DOPAC levels in the
prefrontal cortex then. females

(see lower graph, Figure 4)

[sex main effect, F(l,18) = 4.70, p < .05].
DA levels in the dorsal striatum varied according to
both sex and drug, as only male rats pre-exposed to MDMA
showed a significant decline in striat~l DA levels (see
upper graph, Figure 5)
F(l,18)

= 4.79, p

[drug x sex interaction,

.05]. DOPAC levels in the dorsal

<

striatum did not vary according to group (see lower graph,
Figure 5). DA and DOPAC levels in the hippocampus were
nearly undetectable, so results were not reported.
Effects of MDMA on PKA Activity
Rats pre-exposed to MDMA during the preweanling
period showed a significant decline in PKA activity in the
prefrontal cortex (see Figure 6)
F(l,18)

= 10.85, p

<

[drug main effect,

.05]. Examination of the hippocampus

also revealed that MDMA exposure caused a significant
reduction in PKA activity (see Figure 7)

[drug main

effect, F(l,18) = 6.66, p < .05]. MDMA-exposure did not
significantly affect dorsal striatal PKA activity,
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although female rats had greater PKA activity in the
striatum then male rats [see Figure 8]
F(l,18)

= 5.33, p

<

(drug main effect,

.05).
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CHAPTER FOUR
DISCUSSION
Rationale
Convincing evidence now exists that MDMA exposure
induces both acute and chronic behavioral and
neurochemical changes (Bhattacharya et al., 1998; Commins
et al., 1987; Marston et al., 1999; Morgan, 1999; Nash

&

Nichols, 1991; O'Shea et al., 1998). Although the exact
method by which MDMA induces neurotoxicity remains to be
elucidated, systemic administration of MDMA appears to
cause selective and pronounced alterations in both central
serotonergic and dopaminergic functioning (Battaglia et
al., 1988; Hotchkiss

&

Gibb, 1980; Insel et al., 1989;

Ricaurte et al., 1988). Even though there is sufficient
data to indicate that MDMA produces neurochemical
alterations in adults, little is known about the possible
adverse effects of MDMA exposure on early brain
development and functioning. Thus, the purpose of the
present study was to determine whether exposure to MDMA
during the preweanling period produced long-term changes
in various indices of 5-HT and DA functioning.
To that end, male and female rats were pre-exposed to
MDMA (20 mg/kg, twice daily) on PD 11-20 and then
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sacrificed on PD 90. Neurotoxic damage to 5-HT and DA
terminals was determined by measuring decreases in 5-HT,
5-HIAA, DA, and DOPAC levels. Because repeated early
treatment with AMPH and METH causes long-term changes in
PKA activity (Crawford et al., 2000a, 2000b, 2003), we
also examined whether pre-exposure to MDMA would cause a
long-term decline in PKA activity in various brain
regions.
Evidence for MDMA-Induced
Neurotoxicity
Serotonergic and Dopaminergic Functioning
Overall, results from the present study indicate that
MDMA exposure during the preweanling period caused
neurotoxicity in various brain regions. For example,
chronic MDMA exposure produced a significant decrease in
5-HT and DA levels in prefrontal cortex (the metabolites
did not differ). Early exposure to MDMA also caused
long-term reductions in hippocampal 5-HT levels,
suggesting that ~DMA was responsible for hippocampal
neurotoxicity. The dorsal striatum also evidenced some
neurotoxicity, as DA levels, but not 5-HT levels, were
depressed in theJMDMA group. The latter result was
I

surprising, because both MDMA and METH cause robust 5-HT
reductions in adult rat and monkey striatum (De Souza,
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Battaglia, & Insel, 1990; Kankaanpaa et al., 1998; Nash &
Nichols, 1991; O'Callaghan & Miller, 1994; Pu & Vorhees,
1995).
In the present study, MDMA-induced neurotoxicity was
indirectly inferred by measuring regional reductions in
5-HT and DA levels. There is a substantial literature
showing that prolonged reductions in neurotransmitter
levels reflects cellular neurotoxicity (for reviews, see
Commins et al., 1987; Ricaurte et al., 1985; Schmidt et
al., 1986; Stone et al., 1986). For example, decreases in
5-HT and DA concentrations are associated with a loss of
functional 5-HT and DA uptake sites, indicating damage to
both the serotonergic and dopaminergic nerve terminals
(Schmidt, 1987; Schmidt et al., 1987). Furthermore,
Ricaurte et al.

(1985) found morphological evidence of

nerve degeneration in brain regions corresponding to those
in which drug treatments had produced selective
long-lasting reductions in serotonergic neuronal markers.
In addition, histological evidence also revealed
degenerating neuronal cell bodies through out various
brain regions having reduced 5-HT and DA levels (Commins
et al., 1987; Ricaurte· et al., 1985; Schmidt et al.,
1986). Thus, analyzing 5-HT and DA levels, although an
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indirect method for quantifying neuronal damage, is a
valid and recognized measure of neurotoxicity.
PKA Activity
PKA is a central component of the cAMP second
messenger system (Taylor et al., 1990). A number of
studies have suggested that PKA activity is intimately
involved in the mediation of various behaviors, such as
locomotor activity, memory, reward-related learning, and
anxiety (Abel, Nguyen, Barad, Deuel, Kandel, &
Bourtchouladze, 1997; Berringer & Miller, 1998; Micheau &
Riedel, 1999; Schafe & LeDoux, 2000; Tolliver, 1999). This
is of particular interest, because repeated·
psychostimulant treatment alters PKA activity (Crawford et
al., 2000a; 2000b, 2003; Nestler

&

Aghajanian, 1997). More

specifically, recent studies have described long-term
reductions in striatal and accumbal PKA activity following
AMPH (2.5-5.0 mg/kg/day) and METH (40 mg/kg/day) exposure
during the preweanling period; thus, it is possible that
drug-induced changes in PKA activity may have substantial
long-term behavioral impact (Crawford et al., 2000a,
2003) ..
To date, no studies have examined the long-term
effects of developmental exposure to MDMA on PKA activity.
In the present study, rats given MDMA on PD 11-20 showed
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reduced levels of PKA activity in the prefrontal cortex
and hippocampus. Crawford et al.

(2000a, 2000b) have

previously postulated that psychostimulant-induced
alterations in the DA system (e.g., an up-regulation of
D2 -like receptors or a down-regulation of D1 -like
receptors) by altering cAMP system functioning may have
depressed PKA activity (Crawford et al., 2000a, 2000b).
The present results are consistent with this explanation.
However, in the present study we found that MDMA caused a
robust reduction in prefrontal and hippocampal 5-HT
levels. Some of the 5-HT receptor subtypes (i.e., 5-HT 1 a,
5-HT1b, 5-HT1d, 5-HT1e, 5-HT4, 5-HT 6 , & 5-HT7) utilize the
cAMP second messenger system (Cooper et al., 1996), so it
is possible that alterations in 5-HT could be one of the
driving forces

(along with DA) responsible for

MDMA-induced changes in PKA activity. This possibility is
indirectly supported by results showing that those brain
areas exhibiting the greatest reductions in 5-HT levels
also exhibited the greatest reductions in PKA activity.
Although the exact neural mechanisms have not been
determined, it is possible that MDMA's ability to reduce
neuronal 5-HT and DA levels is responsible for the decline
in PKA activity.

51

Although MDMA's actions were generally similar in
both sexes, it is curious that only male rats showed an
MDMA-induced reduction in striatal DA levels. This pattern
of results has been r._eported before,. since male rats are
often found to be more susceptible to
psychostimulant-induced neurotoxicity (for a review, see
Dluzen, 2000). Past research has shown that c~rculating
estrogen reduces the neurotoxic effects of AMPH and METH
(Gao & Dluzen 2001; Wagner, Tekirian, & Cheo, 1993), and
the present results are consistent with the hypothesis
that the neuroprotective effects of estrogen may extend to
MDMA. Additional sex differences were also apparent, as
male rats had lower levels of hippocampal 5-HIAA and
prefrontal DOPAC then female rats. The importance of the
latter findings is uncertain.
Summation
As mentione_d earlier, MDMA reduces TPH activity, 5-HT
transporter sites, and causes degeneration of 5-HT axon
terminals in adult animals (Battaglia et al., 1987, 1988;
O'Shea et al., 1998). MDMA has also been shown to affect
DA functioning in adults. More specifically, MDMA alters
the number of DA transporters, and reduces both TH
activity and DA levels in adult animals (Hotchkiss
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&

Gibb,

1980; Metzer et al., 1998; Nash & Nichols, 1991; Wagner et
al. , 19 8 0) .
Few studies ·have examined whether fetal brain damage
occurs when pregnant dams are exposed to MDMA. However,
available evidence suggests that MDMA exposure during
gestation has little effect on postnatal neurochemical
development (St. Omer et al., 1991). It has also been
reported that preweanling rats pre-exposed to MDMA on PD
1-10 do not exhibit neuronal or behavioral deficits
(Broening et al., 2001; St. Omer et al., 1991). Only
recently has it become clear that exposing rats to MDMA on
PD 11-20 causes long-term deficits in cognitive
functioning (Broening et al., 2001). Importantly, the late
preweanling period in rats (i.e., PD 11-20) is roughly
analogous to the late 3 rd trimester of human brain
development (Bayer, Altman, Russo,

&

Zhang, 1993). Thus,

the present study has provided new evidence suggesting
that MDMA e~posure can cause neurotoxic effects at doses
that approach or mimic those used by recreational MDMA
users (Ricaurte

&

Mccann, 1992). Of special concern are

pregnant MDMA users who expose their unborn fetus is to
MDMA and, in this way, increase the risk of neurological
damage at developmental brain stages.
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More generally, psychological disorders and
psychiatric symptoms, such as panic attacks
(Whitaker-Azmitia & Anderson, 1989), depression (Cohen,
I

1996), and suicidal ideation (Benazzi & Mazzoli, 1991)
have been associated with MDMA use. The question continues
to surface whether there is a causal link between MDMA ~se
and.the development of psychiatric disorders or whether
MDMA exacerbates a neurological condition among
individuals predisposed (Spitzer, Franke, Walter,
Buechler, .Wunderlich, Schwab, Kovar, Hermle,

&

Gron,

2001). If MDMA is neurotoxic in humans, as has been shown
in other species, then it is likely that the wide-spread
use of MDMA will present a major public health problem in
years to come.
Conclusion
The present study has demonstrated that repeated
exposure to MDMA produces long-term damage to serotonergic
and dopaminergic neurons in various regions of rat brain.
This conclusion is supported by data showing that MDMA
pre-exposure:

(a) decreased 5-HT levels in prefrontal

corte.x and hippocampus;

(b) decreased DA levels in

prefrontal cortex and dorsal striatum; and (c) reduced PKA
activity in p~efrontal cortex and hippocampus. Other

54

investigators have examined the effects of early
MDMA-exposure on a variety of behavioral and cognitive
paradigms. For example, data indicate that MDMA exposure
during the late preweanling period causes significant
disruptions in sequential and spatial reference
memory-based learning (Broening et al., 2001). These
behavioral deficits could potentially be accounted for by
MDMA-induced reductions in 5-HT and DA levels, as well as
by changes in PKA activity. Thus, our findings not only
increase our knowledge of the neurochemical changes
produced by early MDMA exposure, they also provide insight
into human brain neurotoxicity_and those MDMA-induced
changes that may be responsible for learning and memory
deficits and psychiatric disorders.
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